Evidence map›Paper›PMID 27861150›Full record

ArticleOncotarget2017

Digital PCR identifies changes in CDH1 (E-cadherin) transcription pattern in intestinal-type gastric cancer.

Raefa Abou Khouzam, Chiara Molinari, Samanta Salvi, Monica Marabelli, Valeria Molinaro, Donata Orioli, Luca Saragoni, Paolo Morgagni, Daniele Calistri, Guglielmina Nadia Ranzani

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Raefa Abou KhouzamDepartment of Biology and Biotechnology, University of Pavia, Pavia, Italy.
Chiara MolinariBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Samanta SalviBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Monica MarabelliDepartment of Biology and Biotechnology, University of Pavia, Pavia, Italy.
Valeria MolinaroDepartment of Biology and Biotechnology, University of Pavia, Pavia, Italy.
Donata OrioliInstitute of Molecular Genetics, Consiglio Nazionale delle Ricerche, Pavia, Italy.
Luca SaragoniPathology Unit, Morgagni-Pierantoni Hospital, Forlì, Italy.
Paolo MorgagniDepartment of General Surgery, Morgagni-Pierantoni Hospital, Forlì, Italy.
Daniele CalistriBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Guglielmina Nadia RanzaniDepartment of Biology and Biotechnology, University of Pavia, Pavia, Italy.
University of Pavia · ITIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITOspedale G.B. Morgagni - L.Pierantoni · ITIstituto di Genetica Molecolare · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

E-cadherin is a cell-cell adhesion protein encoded by CDH1 tumor-suppressor gene. CDH1 inactivating mutations, leading to loss of protein expression, are common in gastric cancer of the diffuse histotype, while alternative mechanisms modulating E-cadherin expression characterize the more common intestinal histotype. These mechanisms are still poorly understood. CDH1 intron 2 has recently emerged as a cis-modulator of E-cadherin expression, encoding non-canonical transcripts. One in particular, CDH1a, proved to be expressed in gastric cancer cell lines, while being absent in the normal stomach. For the first time, we evaluated by digital PCR the expression of CDH1 and CDH1a transcripts in cancer and normal tissue samples from 32 patients with intestinal-type gastric cancer. We found a significant decrease in CDH1 expression in tumors compared to normal counterparts (P = 0.001), which was especially evident in 76% of cases. CDH1a was detected at extremely low levels in 47% of tumors, but not in normal mucosa. A trend was observed of having less CDH1 in tumors expressing CDH1atranscript. The majority of tumors with both a decrease in CDH1 and presence of CDH1a also showed a decrease in miR-101 expression levels. On the whole, the decrease of CDH1 transcript, corresponding to the canonical protein, and the presence of CDH1a, corresponding to an alternative isoform, are likely to perturb E-cadherin-mediated signaling and cell-cell adhesion, thus contributing to intestinal-type gastric carcinogenesis.

Indexed as

AdultAgedAntigens, CDbeta CateninCadherinsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPolymerase Chain ReactionProtein IsoformsStomach NeoplasmsTranscription, GeneticTranscriptomeAntigens, CDbeta CateninCadherinsCDH1 protein, humanProtein IsoformsCDH1 transcriptsdigital-PCR quantificationintestinal-type gastric cancernormal gastric mucosa

Identifiers

PMID27861150
PMCPMC5386649
OpenAlexW2549848844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.